Provided is a method for detecting, with high sensitivity and high specificity, neurodegenerative diseases selected from the group consisting of human Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD), and amyotrophic lateral schlerosis (ALS). A method for detecting neurodegenerative diseases selected from the group consisting of human Alzeimer's disease (AD), frontotemporal lobar degeneration (FTLD), and amyotrophic lateral schlerosis (ALS), the method including the following steps: (i) a step for measuring MARCKS protein phosphorylated on serine 46 in a test specimen collected from a subject, and also measuring non-phosphorylated MARCKS protein; (ii) a step for calculating the DO value represented by Formula 1 from measurement values obtained in step (i) (in the formula, 'pSer46-MARCKS' indicates the quantity of MARCKS protein phosphorylated on serine 46, and 'non-phosphorylated-MARCKS' indicates the quantity of non-phosphorylated MARCKS protein); and (iii) a step for detecting a neurodegenerative disease using the DO value as an index.
DETECTION OF ALZHEIMER'S DISEASE (AD), FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AMYOTROPHIC LATERAL SCHLEROSIS (ALS), PARKINSON'S DISEASE (PD), AND DEMENTIA WITH LEWY BODIES (DLB) INDICATED BY PHOSPHORYLATION OF MARCKS